BACKGROUND & AIMS: The rate of readmission to the hospital 30 days after discharge (30-day readmission rate) is used as a quality measure for hospitalized patients, but it has not been studied adequately for patients with advanced liver disease. We investigated the incidence and factors that predict this rate and its relationship with mortality at 90 days. METHODS: We analyzed data from patients with advanced liver disease who were hospitalized to an inpatient hepatology service at 2 large academic medical centers in 2008. Patients with elective admission and recipients of liver transplants were not included. During the study period, there were 447 patients and a total of 554 eligible admissions. Multivariate analyses were performed to identify variables associated with 30-day readmission and to examine its relationship with mortality at 90 days. RESULTS: The 30-day readmission rate was 20%. After adjusting for multiple covariates, readmission within 30 days was associated independently with model for end-stage liver disease scores at discharge (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.02-1.09; P = .002), the presence of diabetes (OR, 1.78; 95% CI, 1.07-2.95; P = .027), and male sex (OR, 1.73; 95% CI, 1.03-2.89; P = .038). After adjusting for age, sex, and model for end-stage liver disease score at discharge, the 90-day mortality rate was significantly higher among patients who were readmitted to the hospital within 30 days than those who were not (26.8% vs 9.8%; OR, 2.6; 95% CI, 1.36-5.02; P = .004). CONCLUSIONS: Patients with advanced liver disease frequently are readmitted to the hospital within 30 days after discharge; these patients have a higher 90-day mortality rate than those who are not readmitted in 30 days. These data might be used to develop strategies to reduce early readmission of hospitalized patients with cirrhosis.
BACKGROUND & AIMS: The rate of readmission to the hospital 30 days after discharge (30-day readmission rate) is used as a quality measure for hospitalized patients, but it has not been studied adequately for patients with advanced liver disease. We investigated the incidence and factors that predict this rate and its relationship with mortality at 90 days. METHODS: We analyzed data from patients with advanced liver disease who were hospitalized to an inpatient hepatology service at 2 large academic medical centers in 2008. Patients with elective admission and recipients of liver transplants were not included. During the study period, there were 447 patients and a total of 554 eligible admissions. Multivariate analyses were performed to identify variables associated with 30-day readmission and to examine its relationship with mortality at 90 days. RESULTS: The 30-day readmission rate was 20%. After adjusting for multiple covariates, readmission within 30 days was associated independently with model for end-stage liver disease scores at discharge (odds ratio [OR], 1.06; 95% confidence interval [CI], 1.02-1.09; P = .002), the presence of diabetes (OR, 1.78; 95% CI, 1.07-2.95; P = .027), and male sex (OR, 1.73; 95% CI, 1.03-2.89; P = .038). After adjusting for age, sex, and model for end-stage liver disease score at discharge, the 90-day mortality rate was significantly higher among patients who were readmitted to the hospital within 30 days than those who were not (26.8% vs 9.8%; OR, 2.6; 95% CI, 1.36-5.02; P = .004). CONCLUSIONS:Patients with advanced liver disease frequently are readmitted to the hospital within 30 days after discharge; these patients have a higher 90-day mortality rate than those who are not readmitted in 30 days. These data might be used to develop strategies to reduce early readmission of hospitalized patients with cirrhosis.
Authors: Carlos Terra; Mónica Guevara; Aldo Torre; Rosa Gilabert; Javier Fernández; Marta Martín-Llahí; Maria E Baccaro; Miquel Navasa; Conxita Bru; Vicente Arroyo; Juan Rodés; Pere Ginès Journal: Gastroenterology Date: 2005-12 Impact factor: 22.682
Authors: G Gudmundsson; T Gislason; C Janson; E Lindberg; R Hallin; C S Ulrik; E Brøndum; M M Nieminen; T Aine; P Bakke Journal: Eur Respir J Date: 2005-09 Impact factor: 16.671
Authors: J Fernández Gracia; M A Martínez González; J García Rodríguez; A Bueno Cavanillas; P Lardelli Claret; M García Martín Journal: Med Clin (Barc) Date: 1997-01-11 Impact factor: 1.725
Authors: Juan Ramon González; Esteve Fernandez; Víctor Moreno; Josepa Ribes; Mercè Peris; Matilde Navarro; Maria Cambray; Josep Maria Borràs Journal: J Epidemiol Community Health Date: 2005-06 Impact factor: 3.710
Authors: Joseph S Ross; Gregory K Mulvey; Brett Stauffer; Vishnu Patlolla; Susannah M Bernheim; Patricia S Keenan; Harlan M Krumholz Journal: Arch Intern Med Date: 2008-07-14
Authors: Harish Jasti; Eric M Mortensen; David Scott Obrosky; Wishwa N Kapoor; Michael J Fine Journal: Clin Infect Dis Date: 2008-02-15 Impact factor: 9.079
Authors: Kara B Johnson; Emily J Campbell; Heng Chi; Hui Zheng; Lindsay Y King; Ying Wu; Andrew Delemos; Abu Hurairah; Kathleen Corey; James M Richter; Raymond T Chung Journal: Dig Dis Sci Date: 2013-08-30 Impact factor: 3.199
Authors: Benedict Morath; Tanja Mayer; Alexander Francesco Josef Send; Torsten Hoppe-Tichy; Walter Emil Haefeli; Hanna Marita Seidling Journal: Br J Clin Pharmacol Date: 2017-06-14 Impact factor: 4.335
Authors: Rachel A Elliott; Koen D Putman; Matthew Franklin; Lieven Annemans; Nick Verhaeghe; Martin Eden; Jasdeep Hayre; Sarah Rodgers; Aziz Sheikh; Anthony J Avery Journal: Pharmacoeconomics Date: 2014-06 Impact factor: 4.981
Authors: Jejo D Koola; Sam B Ho; Aize Cao; Guanhua Chen; Amy M Perkins; Sharon E Davis; Michael E Matheny Journal: Dig Dis Sci Date: 2019-09-17 Impact factor: 3.199
Authors: Michael A Dunn; Deborah A Josbeno; Amit D Tevar; Vikrant Rachakonda; Swaytha R Ganesh; Amy R Schmotzer; Elizabeth A Kallenborn; Jaideep Behari; Douglas P Landsittel; Andrea F DiMartini; Anthony Delitto Journal: Am J Gastroenterol Date: 2016-08-30 Impact factor: 10.864